94 results
20-F/A
2023 FY
SPRC
SciSparc Ltd
2 May 24
Annual report (foreign) (amended)
9:18am
, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice Daily Oral SCI-110 in Treating Adults with Tourette Syndrome … to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome, which agreement was subsequently updated
425
SPRC
SciSparc Ltd
12 Apr 24
Business combination disclosure
9:23am
of the Israeli Ministry of Transport and Road Safety, except for any noncompliance, either individually or in the aggregate, which would not be material
6-K
EX-99.1
SPRC
SciSparc Ltd
11 Apr 24
Agreement and Plan of Merger
4:05pm
and Road Safety, except for any noncompliance, either individually or in the aggregate, which would not be material to the Company. No investigation
6-K
EX-99.1
SPRC
SciSparc Ltd
15 Mar 24
SciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical Trial
8:00am
.”
The clinical trial aims to rigorously evaluate the safety, tolerability, and efficacy of SCI-210 in comparison to CBD monotherapy for the treatment
6-K
EX-99.2
ffvec
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
6-K
EX-99.3
i41vc
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
6-K
EX-99.1
0774nk jugzb
29 Feb 24
Report of Foreign Private Issuer
9:07am
F-1
mayqkb fmci
27 Feb 24
Registration statement (foreign)
4:15pm
6-K
EX-99.1
qhwqy0l1dehzz b29p2
28 Nov 23
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
4:00pm
6-K
EX-99.1
47s0ackwacfi tm
24 Oct 23
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
7:54am
6-K
EX-99.1
bbx4bgdps3oscz 5p1p9
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
EX-99.2
6m58o5d5b3lg14
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
EX-99.1
ruw7apwb6hy 6e05hdo
3 Oct 23
SciSparc Granted European Patent for its Core Technology
7:35am
6-K
EX-99.2
r4puwczuvcs
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.1
seyh2o
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
EX-1.1
d8wiiue1
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm
6-K
EX-99.1
prgp0z7 7nq1
17 Jul 23
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
8:00am
6-K
EX-99.1
824ou70fbkc
30 Jun 23
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
4:10pm
6-K
EX-99.1
xtrnnvj3
21 Jun 23
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
9:08am